PPAR-α activation reduced LPS-induced inflammation in alveolar epithelial cells

Experimental Lung Research

Volumn 41, Issue 7, 2015, Pages 393-403

  Hecker, Matthias ^a   Behnk, Aniella ^a   Morty, Rory Edward ^b   Sommer, Natascha ^a   Vadász, István ^a   Herold, Susanne ^a   Seeger, Werner ^a   Mayer, Konstantin ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

acute lung injury; alveolar epithelial cells; fibrate; inflammation; peroxisome proliferator activated receptor

Indexed keywords

CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PROSTAGLANDIN E2; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA; CXCL2 CHEMOKINE; CXCL2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; CELL LYSATE; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STABLE EXPRESSION; SUPERNATANT; UPREGULATION; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; LUNG ALVEOLUS CELL; LUNG INJURY; METABOLISM; MICROBIOLOGY; RESPIRATORY TRACT MUCOSA;

ANIMALS; CHEMOKINE CXCL2; DINOPROSTONE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; INFLAMMATION; LIPOPOLYSACCHARIDES; LUNG INJURY; MICE; PNEUMOCYTES; PPAR ALPHA; RESPIRATORY MUCOSA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942114833     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2015.1046200     Document Type: Article

References (45)

1. Hecker M, Walmrath HD, Seeger W, Mayer K.: Clinical aspects of acute lung insufficiency (ALI/TRALI). Transfus Med Hemother. 2008; 35 (2): 80-88.
2. Wheeler AP, Bernard GR.: Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet. 2007; 369 (9572): 1553-1564.
3. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS.: Acute respiratory distress syndrome: the Berlin definition. JAM.A. 2012; 307 (23): 2526-2533.
4. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE, Benito S, Epstein SK, Apezteguia C, Nightingale P, Arroliga AC, Tobin MJ,; Mechanical Ventilation International Study Group.: Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAM.A. 2002; 287 (3): 345-355.
5. Matthay MA, Zimmerman GA.: Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol. 2005; 33 (4): 319-327.
6. Reynders V, Loitsch S, Steinhauer C, Wagner T, Steinhilber D, Bargon J.: Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Respir Res. 2006; 7: 104.
7. Poynter ME, Daynes RA.: Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998; 273 (49): 32833-32841.
8. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B.: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999; 274 (45): 32048-32054.
9. Toyama T, Nakamura H, Harano Y, Yamauchi N, Morita A, Kirishima T, Minami M, Itoh Y, Okanoue T.: PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun. 2004; 324 (2): 697-704.
10. Schaefer MB, Pose A, Ott J, Hecker M, Behnk A, Schulz R, Weissmann N, Gunther A, Seeger W, Mayer K.: Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury. Eur Respir J. 2008; 32 (5): 1344-1353.
11. Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, Caputi AP, Cuzzocrea S.: Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha in the development of bleomycin-induced lung injury. Shock. 2005; 24 (6): 547-555.
12. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J.: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999; 99 (24): 3125-3131.
13. Herold S, von Wulffen W, Steinmueller M, Pleschka S, Kuziel WA, Mack M, Srivastava M, Seeger W, Maus UA, Lohmeyer J.: Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol. 2006; 177 (3): 1817-1824.
14. Bi MH, Ott J, Fischer T, Hecker M, Dietrich H, Schaefer MB, Markart P, Wang BE, Seeger W, Mayer K.: Induction of lymphocyte apoptosis in a murine model of acute lung injury-modulation by lipid emulsions. Shock. 2009; 33 (2): 179-188.
15. Hecker M, Zaslona Z, Kwapiszewska G, Niess G, Zakrzewicz A, Hergenreider E, Wilhelm J, Marsh LM, Sedding D, Klepetko W, Lohmeyer J, Dimmeler S, Seeger W, Weissmann N, Schermuly RT, Kneidinger N, Eickelberg O, Morty RE.: Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010; 182 (6): 805-818.
16. Hecker M, Weigand MA, Mayer K.: [Acute respiratory distress syndrome]. Internist (Berl). 2012; 53 (5): 557-566.
17. Ware LB, Matthay M.A.: The acute respiratory distress syndrome. N Engl J Med. 2000; 342 (18): 1334-1349.
18. Weppler A, Issekutz AC.: Alveolar epithelium down-modulates endotoxin-but not tumor necrosis factor alpha-induced activation of endothelium and selectively inhibits neutrophil transendothelial migration. Exp Lung Res. 2008; 34 (7): 425-453.
19. Morello S, Ito K, Yamamura S, Lee KY, Jazrawi E, Desouza P, Barnes P, Cicala C, Adcock IM.: IL-1 beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter. J Immunol. 2006; 177 (10): 7173-7183.
20. Clark RB.: The role of PPARs in inflammation and immunity. J Leukoc Biol. 2002; 71 (3): 388-400.
21. Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ.: The role of PPARs in lung fibrosis. PPAR Res. 2007; 2007: 71323.
22. Shirinsky I, Polovnikova O, Kalinovskaya N, Shirinsky V.: The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study. Rheumatol Int. 2012; 33 (12): 3045-3048.
23. Castillero E, Lopez-Menduina M, Martin AI, Villanua MA, Lopez-Calderon A.: Comparison of the effects of the n-3 polyunsaturated fatty acid eicosapentaenoic and fenofibrate on the inhibitory effect of arthritis on IGF1. J Endocrinol. 2011; 210 (3): 361-368.
24. Michalik L, Wahli W.: PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008; 2008: 134059.
25. Goto M.: A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol. 2010; 20 (3): 238-243.
26. Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, Lytle C, Straus DS.: Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology. 2007; 133 (1): 108-123.
27. Krysiak R, Gdula-Dymek A, Okopien B.: Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol. 2011; 107 (7): 1010-1018 e1.
28. Kleemann R, Bureeva S, Perlina A, Kaput J, Verschuren L, Wielinga PY, Hurt-Camejo E, Nikolsky Y, van Ommen B, Kooistra T.: A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis. BMC Syst Biol. 2011; 5: 125.
29. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ.: Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995; 15 (6): 3012-3022.
30. Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Muia C, Crisafulli C, Caputi AP.: The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol. 2006; 79 (5): 999-1010.
31. Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, Frossard N, Pons F.: PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res. 2005; 6: 91.
32. Paukkeri EL, Leppanen T, Sareila O, Vuolteenaho K, Kankaanranta H, Moilanen E.: PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. Br J Pharmacol. 2007; 152 (7): 1081-1091.
33. Menke C, Goncharov T, Qamar L, Korch C, Ford HL, Behbakht K, Thorburn A.: TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. PLoS One. 6 (1): e14527.
34. Akins DR, Porcella SF, Popova TG, Shevchenko D, Baker SI, Li M, Norgard MV, Radolf JD.: Evidence for in vivo but not in vitro expression of a Borrelia burgdorferi outer surface protein F (OspF) homologue. Mol Microbiol. 1995; 18 (3): 507-520.
35. Laurencikiene J, van Harmelen V, Arvidsson Nordstrom E, Dicker A, Blomqvist L, Naslund E, Langin D, Arner P, Ryden M.: NF-kappaB is important for TNF-alpha-induced lipolysis in human adipocytes. J Lipid Res. 2007; 48 (5): 1069-1077.
36. Hoareau L, Bencharif K, Rondeau P, Murumalla R, Ravanan P, Tallet F, Delarue P, Cesari M, Roche R, Festy F.: Signaling pathways involved in LPS induced TNFalpha production in human adipocytes. J Inflamm (Lond). 2010; 7: 1.
37. Xing Z, Jordana M, Kirpalani H, Driscoll KE, Schall TJ, Gauldie J.: Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factor-alpha, macrophage inflammatory protein-2, interleukin-1 beta, and interleukin-6 but not RANTES or transforming growth factor-beta 1 mRNA expression in acute lung inflammation. Am J Respir Cell Mol Biol. 1994; 10 (2): 148-153.
38. Calkin AC, Thomas MC.: PPAR agonists and cardiovascular disease in diabetes. PPAR Res. 2008; 2008: 245410.
39. Feletou M, Huang Y, Vanhoutte PM.: Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol. 2011; 164 (3): 894-912.
40. Alvarez de Sotomayor M, Mingorance C, Andriantsitohaina R.: Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries. Atherosclerosis. 2007; 193 (1): 112-120.
41. Rodriguez-Vilarrupla A, Lavina B, Garcia-Caldero H, Russo L, Rosado E, Roglans N, Bosch J, Garcia-Pagan JC.: PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol. 2012; 56 (5): 1033-1039.
42. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC., Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998; 393 (6687): 790-793.
43. Diaz-Gandarilla JA, Osorio-Trujillo C, Hernandez-Ramirez VI, Talamas-Rohana P.: PPAR activation induces M1 macrophage polarization via cPLA 2-COX-2 inhibition, activating ROS production against Leishmania mexicana. Biomed Res Int. 2013: 215283.
44. Lee DL, Wilson JL, Duan R, Hudson T, El-Marakby A.: Peroxisome proliferator-activated receptor-alpha activation decreases mean arterial pressure, plasma interleukin-6, and COX-2 while increasing renal CYP4A expression in an acute model of DOCA-salt hypertension. PPAR Res. 2011; 2011: 502631.
45. Planaguma A, Pfeffer MA, Rubin G, Croze R, Uddin M, Serhan CN, Levy BD.: Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunol. 2010; 3 (3): 270-279.